Arindam Roy, Ph.D.
About Arindam Roy, Ph.D.
Arindam Roy, Ph.D., is the Executive Director of Global Cell Therapy Quality at Bristol Myers Squibb, with extensive experience in quality assurance and control across several leading pharmaceutical companies.
Current Title and Role
Arindam Roy, Ph.D., serves as the Executive Director of Global Cell Therapy Quality at Bristol Myers Squibb. In this position, he oversees the quality assurance and control frameworks for cell therapy products. His role involves ensuring compliance with regulatory standards and enhancing the efficiency of quality processes.
Previous Experience at Biogen
At Biogen, Roy held the position of Head of Site Quality from 2022 to 2023. His responsibilities included managing the quality assurance operations at the site level, implementing quality improvements, and ensuring compliance with regulatory requirements.
Leadership Roles at Merck
Roy's tenure at Merck included serving as the Vaccine Integrated Process Team Quality Head for commercial/MMRV from 2020 to 2022 and as the Director of the North America Stability Unit and Site QC from 2018 to 2020. During his time at Merck, he managed quality assurance processes and led initiatives to improve laboratory quality assurance.
Educational Background
Arindam Roy holds a Ph.D. in Analytical Chemistry from Missouri University of Science and Technology. He also earned an M.Tech. in Modern Methods of Chemical Analysis from the Indian Institute of Technology, Delhi, and an M.Sc. and B.Sc. in Organic Chemistry with honors from Jadavpur University.
Roles in Quality Control and Assurance
Roy has extensive experience in quality control and assurance, having worked as the Site Head of Quality Control at Fresenius Kabi USA from 2016 to 2018 and as the Associate Director of Quality at both Alkermes and Novartis between 2012 and 2016. His roles at these organizations involved implementing quality control systems and ensuring regulatory compliance.